磷酸化DEK通过PBX3驱动转录重编程维持白血病干细胞
该研究通过磷酸化蛋白质组学比较正常造血干祖细胞与白血病干细胞富集群,发现DEK磷酸化是白血病发生的关键修饰。功能实验表明DEK缺失损害LSC维持并增强化疗敏感性,而DEK过表达导致耐药。机制上CK2磷酸化DEK的4S位点,促进GABPA-PBX3转录程序;抑制该轴可选择性清除LSC并与维奈克拉协同。
要点
- DEK-4S磷酸化由CK2催化,是维持LSC的关键翻译后事件。
- DEK缺失增强LSC对阿扎胞苷联合维奈克拉的化疗敏感性。
- CX-4945抑制DEK磷酸化选择性清除LSC,与维奈克拉协同抗AML。
核心结论
- DEK-4S磷酸化维持LSC并驱动PBX3转录程序,靶向CK2-DEK轴是AML的LSC特异性治疗策略。
研究设计与样本
- 研究对正常造血干祖细胞与LSC富集群进行磷酸化蛋白质组学分析。
- 使用MLL-AF9和HOXA9/MEIS1驱动AML小鼠模型及患者来源异种移植模型进行功能验证。
主要发现
- DEK缺失损害LSC维持和AML进展,DEK过表达赋予化疗耐药。
- DEK招募GABPA上调PBX3,该相互作用依赖DEK的Ser301/303/306/307(4S)磷酸化。
- CK2直接磷酸化DEK-4S位点;4S突变或CX-4945处理选择性清除LSC而保留正常HSPC。
- CX-4945联合维奈克拉促进LSC凋亡并抑制PBX3驱动转录程序,体外和体内均显示协同抗AML效应。
临床怎么用
- 临床分期CK2抑制剂CX-4945联合维奈克拉可能作为靶向LSC的AML治疗策略。
- DEK-4S磷酸化状态或可作为LSC特异性治疗靶点的生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Leukemia stem cells (LSCs) drive acute myeloid leukemia (AML) initiation, relapse, and chemoresistance, yet the core posttranslational events sustaining LSC maintenance remain poorly defined. Here, through phosphoproteomic profiling of normal hematopoietic stem and progenitor cells (HSPCs) vs LSC-enriched populations, we identified DEK phosphorylation as a critical modification during leukemogenesis. Functional studies in MLL-AF9- and HOXA9/MEIS1-driven AML mouse models, as well as patient-derived xenografts, demonstrate that DEK deficiency impairs LSC maintenance and AML progression. Moreover, DEK deletion enhances LSC chemosensitivity to the standard-of-care combination of azacitidine and venetoclax, whereas DEK overexpression confers robust chemoresistance. Mechanistically, DEK recruits the transcription factor GA repeat binding protein α (GABPA) to upregulate the transcriptional cofactor PBX3, a key oncogenic driver in AML, thereby sustaining the leukemogenic transcriptional program. This DEK-GABPA interaction strictly depends on DEK phosphorylation at Ser301/303/306/307 (the 4S sites), which stabilizes the conformation of the DEK-GABPA complex. We identify casein kinase 2 (CK2) as the upstream kinase that directly phosphorylates DEK-4S sites. Importantly, blockade of DEK phosphorylation via 4S site mutagenesis or treatment with the clinical-stage CK2 inhibitor CX-4945 selectively depletes LSCs while sparing normal HSPCs. Furthermore, combining CX-4945 with venetoclax promotes LSC apoptosis and represses the PBX3-driven leukemogenic transcriptional program, exhibiting synergistic anti-AML effects both in vitro and in vivo. Collectively, our findings uncover a previously unrecognized phosphorylation event (DEK-4S phosphorylation) that sustains LSCs and establish the CK2-DEK axis as a promising LSC-specific therapeutic strategy for AML.
引用
- Lei Y, Lai Y, Li Y, et al. Phosphorylated DEK sustains leukemia stem cells by enabling PBX3-driven transcriptional reprogramming. Blood. 2026. PMID: 42378254. doi:10.1182/blood.2025032710
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。